Adrenomedullin (ADM) acts in a site-specific manner within autonomic centers of the brain to modulate mean arterial pressure (MAP). To determine the role of ADM in the pontine autonomic center, the lateral parabrachial nucleus (LPBN), we used urethane-anesthetised adult SpragueDawley male rats to test the hypothesis that ADM increases MAP at this site through glutamateand NO-dependent mechanisms. ADM microinjected into the LPBN increased MAP in a dosedependent manner. The pressor effect of ADM (0.01 pmol) had a peak value of 11.9 ± 1.9 mmHg at 2 minutes and lasted for 7 minutes. We demonstrated that ADM's effect is receptormediated by blocking the effect with the ADM receptor antagonist, ADM . We showed that glutamate mediates ADM's pressor response, as this response was blocked using co-injections of ADM with dizolcipine hydrogen maleate or 6-cyano-7-nitroquinoxaline-2,3-dione, (NMDA) and non-NMDA glutamate receptor antagonists, respectively. We tested the roles of NO with co-injections of ADM with either N5-(1-iminoethyl)-L-ornithine or 7-nitroindazole monosodium salt, non-specific and neuronal NO synthase (NOS) inhibitors, respectively; both inhibitors blocked ADM's pressor effect. Finally, we studied the role of calcium influx in ADM's pressor effect, as intracellular calcium is important in both glutamate and NO neurotransmission. ADM's effect was blocked when nifedipine, an L-type calcium channel blocker, was co-injected with ADM into the LPBN. This study is the first to show that ADM acts in the LPBN to increase MAP through mechanisms dependent on activation of ionotropic glutamate receptors, neuronal and endothelial NOS-mediated NO synthesis, and Ltype calcium channel activation.
Introduction
Discovered in 1993 (20), adrenomedullin (ADM) is a vasoactive peptide that modulates mean arterial blood pressure (MAP) through both central (36, 38, 45, 49) and peripheral (19, 32) mechanisms. Peripherally, ADM acts as a potent hypotensive agent (20) . Because plasma levels of ADM are higher in human hypertensives, it has been suggested that ADM is involved in the physiopathology of hypertension (14, 29, 30) . Hypertension affects one in four adults (44) and is highly correlated with the incidence of stroke and cardiovascular-related deaths. Therefore it is important to understand the roles of ADM in MAP regulation.
Although ADM acts as vasodilator in the periphery (12, 28) , microinjections of ADM into various regions of the central nervous system (CNS) either decrease (49) or increase (36, 38, 45) MAP in rats, illustrating that ADM's actions in the CNS are site-specific. Microinjections of ADM into the rostral ventrolateral medulla of anesthetised rats had a pressor, baroreflexinhibiting effect (45) . Similarly, microinjections of ADM into either the cerebral ventricles of conscious rats (36, 38) or into the area postrema/nucleus of the solitary tract (NTS) of anesthetised rats (1) increased MAP. Conversely, ADM induced a hypotensive effect when injected into the hypothalamic paraventricular nucleus (41, 49) . These results suggest that ADM acts in a pleiotropic manner in the CNS to regulate MAP and that ADM's roles must be separately defined in individual cardiovascular centers.
The lateral parabrachial nucleus (LPBN), an important autonomic nervous center involved in MAP homeostasis, is interconnected with other autonomic cardiovascular centers including the NTS (15) , the hypothalamic paraventricular nucleus (22), and the rostral ventrolateral medulla (13) , and contains neurons that express ADM (39) and ADM receptors (ADMR) (43) . In vivo studies performed in rat (6, 16, 18) and cat (2, 7) suggested that the LPBN receives nervous signals related to changes in MAP, illustrated with c-fos staining or electrophysiological recordings. Glutamate plays an important role in mediating cardiovascular responses in the LPBN as microinjections of glutamate in anesthetised rats increased both MAP and heart rate (HR) (24). Moreover, stimulation of cardiac sympathetic afferents in the anesthetised cat activated glutamatergic and neuronal NO synthase-containing neurons in the LPBN (7). Finally, psychological stress in conscious rats activated NO-producing neurons in LPBN (23). Together these studies show that NO and glutamate in the LPBN mediate changes in MAP and that ADM may act in the LPBN to affect MAP.
ADM acts through two specific metabotropic receptors that are widely distributed in the brain (42, 43). These receptors are formed by the calcitonin-receptor-like-receptor (CLRL) and receptor activity-modifying proteins (RAMPs) 2 or 3 (10, 25) . ADM binds to its receptors and activates intracellular signalling pathways (27, 31, 40, 48) which further increase the intracellular calcium concentration (46) (47) (48) to stimulate NO production (21). Our findings support the role of NO and glutamate in mediating at least some of ADM's central effects on MAP in the rostral ventrolateral medulla and paraventricular nucleus of anesthetised rats, as inhibition of NO synthesis or blockade of glutamate ionotropic receptors in these centers abolished ADM's effects (45, 49) . Furthermore, our in vitro studies confirm that ADM stimulates NO production in SK-N-SH human neuroblastoma cells (48) and in primary rat hypothalamic neuron cultures (47) . ADM also regulates the activity of L-type calcium channels to facilitate calcium entry into the cell (48) , to potentially contribute to a greater activation of glutamate NMDA receptors (4, 35) and to stimulation of NO synthesis (21). Although these findings address the cellular effects of ADM in other autonomic centers of the brain, the interactions among these elements in mediating the effects of ADM in the LPBN remain to be elucidated.
We used urethane-anesthetised male rats to test the hypothesis that ADM acts in the LPBN to increase MAP and HR through glutamate-and/or NO-mediated mechanisms. To determine whether these effects are ADMR-mediated we attempted to block them with the ADMR-specific antagonist, ADM 22-52. Finally, to define the roles of glutamate, NO, and calcium-mediated mechanisms in ADM's effect on MAP, we co-injected ADM with glutamate receptor antagonists, NOS inhibitors, or an L-type calcium channel blocker into the LPBN.
Materials and Methods
Animals. Adult Male Sprague-Dawley rats (350-400 g) were purchased from the Biological Animal Center, University of Alberta, housed in a 12:12-h light-dark cycle at 22°C, and given food and water ad libitum. All surgical and handling protocols were approved by the local Animal Welfare Committee.
Preparation of animals. Rats were anesthetized with urethane (1.75 g/kg, intraperitoneal; Sigma Chemical, St. Louis, MO); additional anesthetic was given as needed during each experiment. Body temperature was monitored with a rectal thermometer and maintained at 37°C with a heating pad.
The left femoral artery was cannulated using PE-50 tubing (Becton Dickinson, Sparks, MD) and mean arterial blood pressure (MAP) and heart rate (HR) were measured using a pressure transducer connected to a computer-based acquisition system DI-150 RS (DATAQ Instruments, Akron, OH).
Rats were secured into a stereotaxic device (David Kopf Instruments, Tujunga, CA, U.S.A.) and a guide cannula (C315G; Plastics One, Wallingford, CT) was lowered into the left LPBN according to the coordinates: -0.7-1.3 mm posterior, 2.0-2.4 mm lateral, and 2.7-3.3 mm dorsal to the interaural zero (34) . An internal cannula (C315I; Plastics One) was connected to a syringe filled with pharmacological agents via PE-50 tubing and was inserted into the guide cannula. Drugs were injected into the LPBN using an electronic infusion pump (Harvard Apparatus, Holliston, MA). All injections were made in a volume of 100 nl over 1 minute. (Fig. 3) . ADM 22-52 alone (0.01 pmol) did not affect the MAP when microinjected into the LPBN (Fig. 3 and Table 1 ).
Effects of ADM on MAP are mediated by L-glutamate ionotropic receptors in the LPBN
The effects of ADM on MAP in the LPBN were blocked when ADM (0.01 pmol) was coinjected with MK-801 (500 pmol), a selective NMDA receptor antagonist (50 pmol; Fig. 4 ). Coinjection of ADM with the selective non-NMDA receptor antagonist CNQX also blocked the ADM-induced increase in MAP (Fig. 4) . MK-801 (500 pmol) or CNQX (50 pmol) , microinjected alone into LPBN, did not affect MAP (Table 1) . These results suggest that ADM acts in the LPBN to increase MAP through a mechanism dependent on the activation of ionotropic glutamate receptors.
Effects of ADM in the LPBN on MAP are mediated by NO produced by nNOS
The increase in MAP was blocked when ADM (0.01 pmol) was co-injected into the LPBN with L-NIO (200 pmol), a non-specific NO synthase inhibitor (Fig. 5) . Furthermore, the neuronal NO synthase inhibitor, 7-NiNa (0.05 pmol), co-injected with ADM (0.01 pmol) into the LPBN, blocked the ADM-induced increase in MAP (Fig. 5) . Neither L-NIO (200 pmol) nor 7-NiNa (0.05 pmol), microinjected alone into LPBN, elicited a significant change in MAP compared to saline controls (Table 1 ). These data show that the ADM-induced increase in MAP which occurs after microinjection into LPBN depends on NO produced by neuronal NOS.
The pressor effect of ADM in the LPBN is mediated by a mechanism dependent on activity of Ltype calcium-channels
The pressor effect of ADM in the LPBN was blocked when ADM (0.01 pmol) was injected into the ipsilateral LPBN 15 minutes after the L-type calcium-channel blocker, nifedipine (0.1 pmol) (Fig. 6) . Nifedipine at 0.1 pmol was chosen in these experiments because it did not significantly affect MAP when injected alone (Table 1) . To confirm that nifedipine specifically blocked ADM's effects on MAP, ADM (0.01 pmol) was then microinjected into the contralateral LPBN, in the absence of nifedipine. These contralateral injections of ADM consistently elicited increases in MAP that were not significantly different from those described for single ADM (0.01 pmol) injections (Figs. 2 and 6 ). These results demonstrate that the pressor effect of ADM is mediated by intracellular calcium.
Discussion
In our study we show for the first time that ADM increases MAP in a dose-dependent manner when microinjected into the LPBN, a major cardiovascular center in the brain. The pressor effect of ADM is receptor-mediated as the specific ADMR antagonist, ADM 22-52, blocked this effect. Moreover, ADM's pressor effect depends on the activation of glutamate receptors because it was blocked when ADM was co-injected with either NMDA or non-NMDA receptor antagonists. The pressor effect of ADM in the LPBN is also mediated by NO as it was abolished when NO synthesis was blocked in the LPBN. Finally, ADM's effect is dependent on intracellular calcium as nifedipine, a specific L-type calcium channel blocker, abolished the pressor effect when microinjected into the LPBN before ADM. Together, our data show that ADM increases MAP in the LPBN through mechanisms dependent on glutamate, NO, and Ltype calcium channel activity.
The concentration of ADM (0.01 pmol) used in our study is similar to the concentrations found to exert a pressor effect in the rostral ventrolateral medulla (45) and a depressor effect in the hypothalamic paraventricular nucleus (49). We demonstrated that ADM's effects are specific to the LPBN, as no pressor effects were obtained when ADM was injected outside the LPBN. In addition, our data show that ADM's actions in the LPBN are mediated by ADMR, as ADM 22-52 , an ADMR specific antagonist, blocked ADM's effect when both agents were injected together.
In the present study we show that ADM acts in the LPBN through a glutamate receptordependent mechanism, as we were able to block ADM's effect by co-injecting ADM with either Our results establish that ADM's pressor effect in the LPBN is also dependent on NO produced by nNOS, as inhibition of NO synthesis with either L-NIO or 7-NiNa (non-specific NOS and nNOS inhibitors, respectively) effectively blocked this effect. ADM's role in potentiating NO synthesis is also suggested by our in vitro studies showing that ADM stimulates both NO release from human neuroblastoma cells and NO production from primary rat hypothalamic neurons (47, 48) . These data are further supported by studies suggesting that NO mediates the ADM-induced cardiovascular changes in the hypothalamic paraventricular nucleus and rostral ventrolateral medulla (45, 49) . In addition, as discussed above, ventricular stimulation with bradykinin activated nNOS-containing neurons in the LPBN of anesthetised cats (7).
Moreover, in conscious rats, stress led to c-fos activation in NO-producing neurons of the LPBN It has also been shown that glutamate stimulates NO synthesis in a calcium-dependent manner and that NO then acts through a feedback mechanism to modulate the activity of presynaptic neurons; in this way, NO is thought to stimulate the release of neurotransmitters, including glutamate (26). We have shown that L-type calcium channels are required for the stimulation of NO production by ADM in neuroblastoma cells (48) and we show here that ADM's pressor effect in the LPBN is dependent on L-type calcium channels.
Perspectives and Significance
Our study provides data important for understanding ADM's central actions in MAP regulation. We have used site-specific microinjections of ADM in anesthetised rats to show that ADM acts in the LPBN to increase MAP through complex mechanisms dependent on glutamate receptor activation, NO synthesis, and L-type calcium channel activation. Additional studies in conscious animals will be needed to fully establish the physiological significance of ADM signalling in the LPBN. Future research is also required, not only to define the nature of ADMinduced cellular interactions between glutamate and NO, but to explore the possibility that dysfunctions in ADM signalling in the LPBN contribute to the development of hypertension. 
